These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 24682465)

  • 1. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
    Maemondo M; Inoue A; Sugawara S; Harada T; Minegishi Y; Usui K; Miwa K; Morikawa N; Kambe M; Ube K; Watanabe K; Ishimoto O; Sakakibara T; Gemma A; Nukiwa T
    Oncologist; 2014 Apr; 19(4):352-3. PubMed ID: 24682465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
    Belani CP; Einzig A; Bonomi P; Dobbs T; Capozzoli MJ; Earhart R; Cohen LJ; Luketich JD
    Ann Oncol; 2000 Jun; 11(6):673-8. PubMed ID: 10942054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
    Saito H; Nakagawa K; Takeda K; Iwamoto Y; Ando M; Maeda M; Katakami N; Nakano T; Kurata T; Fukuoka M
    Am J Clin Oncol; 2012 Feb; 35(1):58-63. PubMed ID: 21293243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
    Quoix E; Zalcman G; Oster JP; Westeel V; Pichon E; Lavolé A; Dauba J; Debieuvre D; Souquet PJ; Bigay-Game L; Dansin E; Poudenx M; Molinier O; Vaylet F; Moro-Sibilot D; Herman D; Bennouna J; Tredaniel J; Ducoloné A; Lebitasy MP; Baudrin L; Laporte S; Milleron B;
    Lancet; 2011 Sep; 378(9796):1079-88. PubMed ID: 21831418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
    Belani CP;
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):4-9. PubMed ID: 12170445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
    Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
    Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
    Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
    J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
    Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A
    Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer.
    Sakakibara T; Inoue A; Sugawara S; Maemondo M; Ishida T; Usui K; Abe T; Kanbe M; Watanabe H; Saijo Y; Nukiwa T
    Ann Oncol; 2010 Apr; 21(4):795-799. PubMed ID: 19815651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial.
    Ramalingam S; Barstis J; Perry MC; La Rocca RV; Nattam SR; Rinaldi D; Clark R; Mills GM; Belani CP
    J Thorac Oncol; 2006 Mar; 1(3):240-4. PubMed ID: 17409863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
    Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
    J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
    Furuiye M; Ishiwata N; Jin Y; Miyashita Y; Takano S; Yoshizawa M; Miyake S; Inase N; Yoshizawa Y
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1133-8. PubMed ID: 18633251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer.
    Takayama K; Ichiki M; Tokunaga S; Inoue K; Kawasaki M; Uchino J; Nakanishi Y
    Oncologist; 2019 Nov; 24(11):1420-e1010. PubMed ID: 31332099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
    Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H
    Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.
    Kawahara M; Atagi S; Komuta K; Yoshioka H; Kawasaki M; Fujita Y; Yonei T; Ogushi F; Kubota K; Nogami N; Tsuchiya M; Shibata K; Tomizawa Y; Minato K; Fukuoka K; Asami K; Yamanaka T;
    Anticancer Res; 2013 Oct; 33(10):4631-7. PubMed ID: 24123041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study.
    Rozzi A; Nardoni C; Corona M; Restuccia MR; Falbo T; Lanzetta G
    J Chemother; 2010 Dec; 22(6):419-23. PubMed ID: 21303751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.
    Pereira JR; Cheng R; Orlando M; Kim JH; Barraclough H
    Drugs R D; 2013 Dec; 13(4):289-96. PubMed ID: 24277116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
    Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
    Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.